bradykinesia-cbs

bradykinesia-cbs

Overview

bradykinesia-cbs

Overview

Bradykinesia—slowness of movement—is a core feature of parkinsonism and one of the cardinal motor symptoms in corticobasal syndrome (CBS). However, the presentation and pathophysiology of bradykinesia in CBS differs significantly from idiopathic Parkinson's disease (PD), reflecting the distinct underlying neuropathology [1]. Unlike PD, which is characterized by alpha-synuclein Lewy body pathology, CBS is primarily a 4-repeat (4R) tauopathy affecting the cortex and basal ganglia, leading to a fundamentally different pattern of motor impairment[@koga2022] [2][3].

The term "corticobasal degeneration" (CBD) was originally described by Rebeiz and colleagues in 1968 as "corticodentatonigral degeneration with neuronal achromasia," recognizing the distinctive neuropathological features that distinguish this disorder from other parkinsonian conditions [4][@koga2022]. The clinical syndrome of CBS manifests with asymmetric apraxia, cortical sensory loss, alien limb phenomena, and prominent bradykinesia that responds poorly to dopaminergic medications[@cordato2001] [5][6].

Clinical Features

Characteristics of Bradykinesia in CBS

Bradykinesia in CBS presents with several distinctive characteristics that differentiate it from other parkinsonian disorders:

• Generalized slowing of voluntary movements across all body regions
• Progressive reduction in movement amplitude during repeated tasks
• Decreased movement speed that is not solely attributable to rigidity
• Often more pronounced in the morning or after rest periods

• Rapid decrement in movement amplitude with repeated tasks (task-specific fatigue)
• "Micrographia" (progressive decrease in handwriting size) is common [7]
• Difficulty with sequential motor tasks and bimanual coordination
• Performance often worsens with continued activity rather than improving

• Markedly asymmetric onset, typically affecting one side of the body initially
• The most affected limb often corresponds to the contralateral cortical region with greatest pathology
• Frequently the presenting symptom that brings patients to medical attention
• Contralateral symptoms usually appear within 1-2 years of onset [8]

• Rapid progression compared to idiopathic Parkinson's disease
• Functional disability develops within 2-5 years of symptom onset
• Often progresses to bilateral involvement within 3-4 years
• Axial symptoms (gait, postural instability) develop early compared to PD

Specific Manifestations

Limb Bradykinesia

• Reduced arm swing during walking, often asymmetric
• Difficulty with fine motor tasks (buttoning, writing, using utensils)
• Slow finger tapping with progressive decrement in amplitude
• Impaired hand dexterity and coordination
• Difficulty with alternating movements (pronation-supination)

Facial Bradykinesia

• Reduced facial expression (hypomimia), often asymmetric
• Decreased blinking rate leading to staring appearance
• Monotonous speech with reduced prosody
• Hypophonia (reduced speech volume)
• Difficulty with facial mimicry and emotional expression

Axial Bradykinesia

• Reduced trunk rotation during walking
• Difficulty rising from a chair without assistance
• Generalized slowness of all axial movements
• Early postural instability and falls
• Shuffling gait with reduced stride length

Oculomotor Bradykinesia

• Slow smooth pursuit eye movements
• Difficulty with saccadic initiation
• Reduced blink rate leading to dry eyes
• Impaired visuomotor coordination

Differences from Parkinson's Disease

The differential diagnosis between CBS and PD is critical for prognostic counseling and treatment planning. Key distinguishing features of bradykinesia in each condition are outlined below [9][10]:

| Feature | CBS Bradykinesia | PD Bradykinesia |
|---------|------------------|-----------------|
| Onset | Asymmetric from onset | Often starts unilateral |
| Symmetry | Remains markedly asymmetric | Becomes more symmetric over time |
| Response to levodopa | Poor to minimal response | Excellent response (70-80%) |
| Sensory tricks | Rarely helpful | Can reduce rigidity/tremor |
| Associated cortical signs | Common (apraxia, alien limb, cortical sensory loss) | Absent |
| Progression | Faster (2-5 years to disability) | Slower (10-15 years to disability) |
| Resting tremor | Less common | Common (60-70%) |
| Cognitive impairment | Early, prominent | Late, variable |
| Tremor character | Postural/action tremor common | Resting tremor classic |

Pathophysiological Basis for Differences

The distinct clinical features of bradykinesia in CBS versus PD stem from fundamentally different neuropathological mechanisms [11][12]:

Sensory Tricks in CBS

An interesting phenomenon reported in CBS is that bradykinesia may occasionally improve with sensory tricks—stimuli that temporarily reduce motor symptoms. This is more commonly associated with dystonia but has been documented in CBS, suggesting unique pathophysiological mechanisms [16]. Sensory tricks in CBS may include:

• Light touch to the affected limb
• Vibration applied to the skin
• Proprioceptive facilitation
• Visual guidance of movement

Pathophysiology

Neuroanatomical Basis

Bradykinesia in CBS results from dysfunction at multiple levels of the motor system [17][18]:

Basal Ganglia Dysfunction

The basal ganglia normally function as a selection mechanism, facilitating desired movements while suppressing competing ones. In CBS, tau pathology disrupts this selection process, leading to slowed movement initiation and execution [19].

Cortical Contributions

The cortical pathology in CBS is more pronounced than in PD, explaining the presence of apraxia, alien limb, and cortical sensory loss—features absent in typical PD [20].

Tau Pathology

Unlike PD (alpha-synuclein), CBS is primarily a 4R tauopathy [21][22]:

• 4R tau accumulation in neurons and glia of basal ganglia and cortex
• Astrocytic plaques (distinct from AD neuritic plaques)
• Coiled bodies in oligodendrocytes
• Different pattern of neurodegeneration compared to PD
• Progression follows cortico-striatal-thalamic circuits rather than brainstem

Mechanism of Bradykinesia

The bradykinesia in CBS results from multiple converging mechanisms:

Neuroimaging Correlates

Structural and functional neuroimaging in CBS reveals [25][26]:

• MRI: Asymmetric cortical atrophy, particularly in frontal and parietal regions
• FDG-PET: Hypometabolism in premotor cortex, SMA, and basal ganglia
• DaTscan: Preserved dopamine transporter binding (less loss than PD)
• DTI: Disruption of corticospinal tract integrity
• PET with tau ligands: Increased 4R tau binding in affected cortical regions

Assessment

Clinical Testing

Standard Bedside Examinations

• Patient taps thumb and index finger together
• Count repetitions in 10 seconds
• Assess amplitude reduction over time
• Document any decrement pattern (progressive slowing)

• Patient opens and closes hands rapidly
• Assess speed, amplitude, and smoothness
• Note any clumsiness or dyspraxia

• Patient rotates forearms alternately
• Assess smoothness, speed, and range of motion
• Note any apraxia or difficulty with the task

• Patient lifts foot and taps on floor rapidly
• Assess speed and amplitude
• Document any decrement over 10 repetitions

• Observe gait, arm swing, stride length
• Note asymmetry of arm swing
• Document shuffling, festination, or freezing

Quantitative Measures

• UPDRS Part III (MDS): Standardized assessment of motor symptoms [27]
• Britewater Mobility Index: Disease-specific for atypical parkinsonism
• Accelerometry: Objective, reproducible measurement of movement
• Kinematic Analysis: Detailed movement parameters including velocity, acceleration
• Electromyography: Assessment of muscle activation patterns
• Quantitative Finger Tapping: Computer-based measurement of tapping dynamics

Rating Scales

Several rating scales incorporate bradykinesia assessment:

Neurophysiological Testing

• Transcranial Magnetic Stimulation (TMS): Assess corticomotor excitability [28]
• Electroencephalography (EEG): Movement-related cortical potentials
• EMG Coherence Analysis: Assess cortical-subcortical connectivity

Treatment

Pharmacological Approaches

Dopaminergic Therapy

Dopaminergic medications are significantly less effective in CBS compared to PD [29][30]:

• Limited to no response in most CBS patients
• May provide modest benefit in some cases (< 20% improvement)
• Trial of high-dose levodopa (up to 1200 mg/day) recommended to confirm non-response
• Response rate much lower than in PD (70-80%)

• May provide modest symptomatic benefit
• Pramipexole, ropinirole, rotigotine
• Often limited by side effects ( hallucinations, edema)

• Variable response
• May provide mild benefit as adjunct therapy
• Selegiline, rasagiline, safinamide

• CBS has less dopamine deficiency than PD
• Primary pathology is cortical, not nigrostriatal
• Postsynaptic basal ganglia dysfunction
• Tau pathology affects movement circuitry differently

Alternative Approaches

• May help some patients with motor symptoms
• Particularly for dyskinesias if they develop
• Limited evidence in CBS specifically

• For associated cognitive slowing (bradyphrenia)
• Modafinil, methylphenidate
• Address daytime somnolence

• Antisense oligonucleotides targeting MAPT gene
• Tau aggregation inhibitors (in trials)
• Immunotherapy approaches (active and passive vaccination)

Non-Pharmacological Approaches

Physical Therapy

• Aerobic exercise to maintain function
• Resistance training for strength
• Balance exercises to prevent falls
• Tailored to asymmetric presentation

• Cued movement initiation (verbal, visual, auditory)
• External rhythm cues (metronome)
• Task breakdown and practice
• Energy conservation techniques

• Visual cueing (footprints, lines)
• Auditory cueing (rhythm)
• Nordic walking poles
• Treadmill training with body weight support

Occupational Therapy

• Adaptive equipment for daily activities
• Energy conservation techniques
• Home modifications for safety
• Writing aids for micrographia
• Dressing aids for one-handed techniques

Speech Therapy

• For speech and facial bradykinesia
• Lee Silverman Voice Treatment (LSVT) LOUD
• Respiratory strengthening
• Communication strategies

Emerging Therapies

• Anti-tau antibodies in clinical trials
• Could potentially slow disease progression

• AAV-vector delivery of therapeutic genes
• Targeting tau metabolism or neuroprotection

• Disease-modifying compounds in development
• Focus on tau pathology and neuroinflammation

Research Directions

Biomarkers

• DaTscan imaging: Dopamine transporter binding patterns (preserved in CBS vs. PD)
• MRI: Structural changes in basal ganglia and cortex
• FDG-PET: Metabolic patterns differentiating CBS from PD
• Tau PET: 4R tau imaging in basal ganglia and cortex
• CSF biomarkers: Total tau, phosphorylated tau, neurofilament light chain

Clinical Trials

Current therapeutic approaches under investigation include:

Outcome Measures

Key endpoints for clinical trials in CBS include:

• MDS-UPDRS Part III (motor subscore)
• CBS-RS (disease-specific scale)
• Functional independence measures
• Quality of life assessments
• Caregiver burden measures

Cross-References

• [Corticobasal Syndrome](/diseases/corticobasal-syndrome)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Tau Proteins](/proteins/tau)
• [Basal Ganglia](/brain-regions/basal-ganglia)
• [Substantia Nigra](/brain-regions/substantia-nigra)
• [Motor Cortex](/brain-regions/cortex)
• [4R Tauopathies](/mechanisms/4r-tauopathies)
• [Myoclonus in CBS](/diagnostics/myoclonus-cbs)
• [Alien Limb in CBS](/diagnostics/alien-limb-cbs)
• [Apraxia in CBS](/diagnostics/ideomotor-apraxia-cbs)
• [Gait and Falls in CBS](/diagnostics/gait-falls-cbs)

See Also

• [NeuroWiki Home](/home)
• [Diagnostics Overview](/diagnostics/overview)
• [Atypical Parkinsonism](/diseases/atypical-parkinsonism)

References